Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs United Airlines Holdings Inc (UAL) Price & Performance

Amylx Pharmaceuticals IncTrade
United Airlines Holdings IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while United Airlines Holdings Inc trades at $126.9 (market cap $40.17B). The key difference: United Airlines Holdings Inc is far larger — about 15.9× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.

AMLXUAL
Market Cap
$2.53B$40.17B
Sector
HealthIndustrials
52-Week High
$24.19$136.11
52-Week Low
$7.82$85.21
Enterprise Value
$2.28B$57.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

United Airlines Holdings Inc

United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.

The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About United Airlines Holdings Inc

United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.

Read more on UAL